Under a tenth of individuals that would benefit from weight-loss injections like Wegovy are able to get them, states the global health agency as it releases its initial recommendations on the medications.
With more than one billion people worldwide currently classified as obese, it is urging more widespread and fairer access to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.
"The new guidance acknowledges that excess weight is a long-term condition that can be addressed with holistic and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major hurdles to broad availability to the jabs that can help people shift considerable weight, explains the body.
Skinny Jab Shortage
Despite the current most optimistic outlook, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – fewer than 10% of the global need, as stated by the health organization.
The advice encourages nations and manufacturers to expand availability, through approaches including licensing agreements.
A patent on semaglutide – the primary ingredient of a leading brand – is set to lapse in several nations in 2026.
The Way Obesity Drugs Operate
GLP-1 drugs replicate a body's own hormone to slow digestion, reduce hunger and boost satiety so individuals reduce food intake.
Patients usually begin shedding pounds after several weeks of beginning the regular doses.
Evidence suggests users may regain a significant portion a year later of discontinuing the drug, because their usual appetite come back.
Being overweight or obese elevates your risk for contracting medical conditions, including diabetes, cardiovascular issues, stroke, and specific malignancies.
Obesity concerns people in every country and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
